Estradiol; Norethindrone Acetate; Relugolix Patent Expiration

Estradiol; Norethindrone Acetate; Relugolix is Used for managing heavy menstrual bleeding and pain associated with uterine fibroids in premenopausal women, as well as pain associated with endometriosis. It was first introduced by Sumitomo Pharma Switzerland Gmbh in its drug Myfembree on May 26, 2021.


Estradiol; Norethindrone Acetate; Relugolix Patents

Given below is the list of patents protecting Estradiol; Norethindrone Acetate; Relugolix, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Myfembree US11793812 Methods of treating endometriosis May 03, 2038 Sumitomo Pharma
Myfembree US11033551 Methods of treating uterine fibroids Sep 29, 2037 Sumitomo Pharma
Myfembree US11957684 Treatment of heavy menstrual bleeding associated with uterine fibroids Sep 29, 2037 Sumitomo Pharma
Myfembree US11795178 Compositions of thienopyrimidine derivatives Sep 27, 2033 Sumitomo Pharma
Myfembree US7300935 Thienopyrimidine compounds and use thereof Jan 28, 2025 Sumitomo Pharma
Myfembree US8058280 Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof Jan 28, 2025 Sumitomo Pharma
Myfembree US9346822 Thienopyrimidine compounds and use thereof Feb 17, 2024

(Expired)

Sumitomo Pharma



Estradiol; Norethindrone Acetate; Relugolix's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List